Comparable stake leader
BlackRock, Inc.
SEC ownership of BIOMARIN PHARMACEUTICAL INC
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001048477.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
02 Jun 2026
- Public ticker
- BMRN on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
BlackRock, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
BlackRock, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
02 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001048477
- Issuer location
- Novato, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of BIOMARIN PHARMACEUTICAL INC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
02 Jun 2026
13F
13D/G
3/4/5
Lead comparable stake: 9.1%
13D/G row: BlackRock, Inc.
Showing 1-8 of 50 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 9.1%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
9.1%
PRIMECAP MANAGEMENT CO/CA/
8.2%
VANGUARD CAPITAL MANAGEMENT LLC
5.2%
Capital Research Global Investors
4.8%
VIKING GLOBAL INVESTORS LP
4.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
Company
|
9.1%
from 13D/G
|
$1,119,535,796
19,818,301 shares
|
— | 31 Mar 2026 |
| PRIMECAP MANAGEMENT CO/CA/ |
13D/G
13F
Company
|
8.2%
|
$906,812,938
15,795,383 shares
|
$0 | 30 Jun 2025 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
5.2%
|
$571,295,741
10,113,219 shares
|
$0 | 31 Mar 2026 |
| Capital Research Global Investors |
13D/G
13F
Company
|
4.8%
|
$576,308,252
9,150,655 shares
|
-$241,913,549 | 31 Mar 2025 |
| VIKING GLOBAL INVESTORS LP |
13D/G
13F
Company
|
4.3%
|
$450,729,215
8,322,179 shares
|
-$214,821,957 | 30 Sep 2025 |
| Richard A. Meier |
3/4/5
Director
|
0.07%
|
$7,659,984
126,926 shares
|
— | 31 Dec 2025 |
| Robert J. Hombach |
3/4/5
Director
|
0.03%
|
$2,788,346
49,360 shares
|
— | 02 Jun 2026 |
| Willard H. Dere |
3/4/5
Director
|
0.02%
|
$2,623,395
46,440 shares
|
— | 02 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$3,154,466.
Buys
$0
Insiders: 0
Sells
$3,154,466
Insiders: 3
Net
-$3,154,466
Shares: -52,154
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 52,154
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 3,281 | $0 | $176,682 | -$176,682 |
| 3-6 | 0 | 48,873 | $0 | $2,977,784 | -$2,977,784 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 27 reporting-owner rows connected to BIOMARIN PHARMACEUTICAL INC. Open a relationship link for the CIK-to-CIK filing trail.
Rows
27
Largest Forms 3/4/5 holder
Jean Jacques Bienaime
Net 12M change
-$3,154,466
Latest report
02 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Jean Jacques Bienaime | Director | $55,578,092 | Mixed | 20 May 2024 | ||
| Henry J. Fuchs | President, Worldwide R&D | $15,712,783 | Mixed | 13 Sep 2024 | ||
| Alexander Hardy | Chief Executive Officer, Director | $13,440,443 | Mixed | 17 Mar 2026 | ||
| Brian Mueller | EVP, Chief Financial Officer | $7,721,922 | Mixed | 17 Mar 2026 | ||
| Richard A. Meier | Director | $7,659,984 | Mixed | 31 Dec 2025 | ||
| Elaine J. Heron | Director | $7,466,785 | Mixed | 03 Jun 2024 | ||
| Jeffrey Robert Ajer | EVP, Chief Commercial Officer | $5,535,652 | Filing P/S | 02 May 2024 | ||
| Charles Greg Guyer | EVP, Chief Technical Officer | $5,268,846 | -$996,744 | -16% | Mixed | 17 Mar 2026 |
| George Eric Davis | EVP, Chief Legal Officer | $4,919,427 | -$1,599,103 | -25% | Mixed | 18 Mar 2026 |
| David E. I. Pyott | Director | $3,833,238 | Mixed | 21 May 2024 | ||
| Bryan Lawlis V | Director | $3,194,033 | Mixed | 23 May 2023 | ||
| Gregory R. Friberg | EVP, Chief R&D Officer | $2,790,399 | -$558,619 | -17% | Filing P/S | 07 May 2026 |
| Robert J. Hombach | Director | $2,788,346 | Mixed | 02 Jun 2026 | ||
| Willard H. Dere | Director | $2,623,395 | Mixed | 02 Jun 2026 | ||
| Dennis Slamon | Director | $2,623,169 | Mixed | 18 Mar 2024 | ||
| Cristin Hubbard | EVP, Chief Commercial Officer | $2,399,243 | Mixed | 20 May 2026 | ||
| Elizabeth M. Anderson | Director | $2,369,190 | Mixed | 02 Jun 2026 | ||
| Maykin Ho | Director | $2,005,395 | Mixed | 02 Jun 2026 | ||
| Andrea Acosta | GVP, Chief Accounting Officer | $1,746,598 | Mixed | 30 Apr 2021 | ||
| Rashmi Virendra Ramchandani | VP, Chief Accounting Officer | $1,522,002 | Mixed | 20 Jan 2026 |
Recent insider transactions for BIOMARIN PHARMACEUTICAL INC
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Athena Countouriotis | BMRN | Common Stock | Award | 55.3% | 7,490 | 21,040 | 02 Jun 2026 | Direct | ||
| Timothy P. Walbert | BMRN | Common Stock | Award | 76.6% | 7,490 | 17,270 | 02 Jun 2026 | Direct | ||
| Maykin Ho | BMRN | Common Stock | Award | 26.7% | 7,490 | 35,500 | 02 Jun 2026 | Direct | ||
| Robert J. Hombach | BMRN | Common Stock | Award | 17.9% | 7,490 | 49,360 | 02 Jun 2026 | Direct | ||
| Mark J. Enyedy | BMRN | Common Stock | Award | 55.3% | 7,490 | 21,040 | 02 Jun 2026 | Direct | ||
| Willard H. Dere | BMRN | Common Stock | Award | 19.2% | 7,490 | 46,440 | 02 Jun 2026 | Direct | ||
| Clark Ian T. | BMRN | Common Stock | Award | 107% | 7,490 | 14,490 | 02 Jun 2026 | Direct | ||
| Barbara W. Bodem | BMRN | Common Stock | Award | 55.3% | 7,490 | 21,045 | 02 Jun 2026 | Direct | ||
| Elizabeth M. Anderson | BMRN | Common Stock | Award | 21.7% | 7,490 | 41,940 | 02 Jun 2026 | Direct | ||
| Cristin Hubbard | BMRN | Common Stock | Tax liability | -5.18% | -2,318 | 42,472 | 20 May 2026 | Direct | ||
| Gregory R. Friberg | BMRN | Common Stock | Sale | -5.95% | $176,682 | $53.85 | -3,281 | 51,818 | 07 May 2026 | Direct |
| George Eric Davis | BMRN | Common Stock | Tax liability | -1.59% | -1,273 | 78,560 | 18 Mar 2026 | Direct | ||
| Charles Greg Guyer | BMRN | Common Stock | Tax liability | -1.97% | -1,693 | 84,140 | 17 Mar 2026 | Direct | ||
| Brian Mueller | BMRN | Common Stock | Tax liability | -1.69% | -2,117 | 123,314 | 17 Mar 2026 | Direct | ||
| Alexander Hardy | BMRN | Common Stock | Tax liability | -1.94% | -4,252 | 214,635 | 17 Mar 2026 | Direct | ||
| Cristin Hubbard | BMRN | Common Stock | Tax liability | -2.7% | -1,245 | 44,790 | 17 Mar 2026 | Direct | ||
| Gregory R. Friberg | BMRN | Common Stock | Tax liability | -2.87% | -1,629 | 55,099 | 17 Mar 2026 | Direct | ||
| Cristin Hubbard | BMRN | Common Stock | Award | 50.3% | 15,410 | 46,035 | 16 Mar 2026 | Direct | ||
| Cristin Hubbard | BMRN | Stock Option (Right to Buy Common Stock) | Award | 36,680 | 36,680 | 16 Mar 2026 | Direct | |||
| Gregory R. Friberg | BMRN | Common Stock | Award | 51% | 19,150 | 56,728 | 16 Mar 2026 | Direct | ||
| Gregory R. Friberg | BMRN | Stock Option (Right to Buy Common Stock) | Award | 45,600 | 45,600 | 16 Mar 2026 | Direct | |||
| Charles Greg Guyer | BMRN | Common Stock | Award | 21.2% | 14,990 | 85,833 | 16 Mar 2026 | Direct | ||
| Charles Greg Guyer | BMRN | Stock Option (Right to Buy Common Stock) | Award | 35,680 | 35,680 | 16 Mar 2026 | Direct | |||
| George Eric Davis | BMRN | Common Stock | Award | 22.3% | 14,570 | 79,833 | 16 Mar 2026 | Direct | ||
| George Eric Davis | BMRN | Common Stock | Tax liability | -9.91% | -7,177 | 65,263 | 16 Mar 2026 | Direct | ||
| George Eric Davis | BMRN | Stock Option (Right to Buy Common Stock) | Award | 34,690 | 34,690 | 16 Mar 2026 | Direct | |||
| Brian Mueller | BMRN | Common Stock | Award | 17.6% | 18,740 | 125,431 | 16 Mar 2026 | Direct | ||
| Brian Mueller | BMRN | Stock Option (Right to Buy Common Stock) | Award | 44,600 | 44,600 | 16 Mar 2026 | Direct | |||
| Alexander Hardy | BMRN | Common Stock | Award | 39.9% | 62,440 | 218,887 | 16 Mar 2026 | Direct | ||
| Alexander Hardy | BMRN | Stock Option (Right to Buy Common Stock) | Award | 89,200 | 89,200 | 16 Mar 2026 | Direct | |||
| Charles Greg Guyer | BMRN | Common Stock | Tax liability | -11.4% | -9,109 | 70,843 | 13 Mar 2026 | Direct | ||
| Brian Mueller | BMRN | Common Stock | Tax liability | -8.53% | -9,945 | 106,691 | 13 Mar 2026 | Direct | ||
| Alexander Hardy | BMRN | Common Stock | Tax liability | -1.85% | -2,941 | 156,447 | 13 Mar 2026 | Direct | ||
| Charles Greg Guyer | BMRN | Common Stock | Sale | -17.1% | $996,744 | $60.46 | -16,486 | 79,953 | 11 Mar 2026 | Direct |
| Gregory R. Friberg | BMRN | Common Stock | Sale | -14.4% | $381,937 | $60.38 | -6,326 | 37,578 | 26 Feb 2026 | Direct |
| George Eric Davis | BMRN | Common Stock | Sale | -26.4% | $1,599,103 | $61.36 | -26,061 | 72,453 | 26 Feb 2026 | Direct |
| Charles Greg Guyer | BMRN | Common Stock | Award | 18.7% | 15,222 | 96,439 | 25 Feb 2026 | Direct | ||
| George Eric Davis | BMRN | Common Stock | Award | 18.3% | 15,224 | 98,514 | 25 Feb 2026 | Direct | ||
| Brian Mueller | BMRN | Common Stock | Award | 16.5% | 16,482 | 116,638 | 25 Feb 2026 | Direct | ||
| Rashmi Virendra Ramchandani | BMRN | Common Stock | Award | 25,610 | 25,610 | 20 Jan 2026 | Direct | |||
| Rashmi Virendra Ramchandani | BMRN | Stock Option (Right to Buy Common Stock) | Award | 18,220 | 18,220 | 20 Jan 2026 | Direct | |||
| Richard A. Meier | BMRN | Common Stock | Gift | -0.39% | -500 | 126,926 | 30 Dec 2025 | Direct | ||
| Alexander Hardy | BMRN | Common Stock | Tax liability | -9.42% | -16,570 | 159,388 | 01 Dec 2025 | Direct | ||
| Cristin Hubbard | BMRN | Common Stock | Award | 0.26% | 80 | 30,625 | 31 Oct 2025 | Direct | ||
| Charles Greg Guyer | BMRN | Common Stock | Award | 0.08% | 62 | 81,217 | 31 Oct 2025 | Direct | ||
| Gregory R. Friberg | BMRN | Common Stock | Award | 0.91% | 398 | 43,904 | 31 Oct 2025 | Direct | ||
| Gregory R. Friberg | BMRN | Common Stock | Tax liability | -7.06% | -3,304 | 43,506 | 30 Sep 2025 | Direct |
* marks a reported price that did not pass the local price check.